Concepedia

Ilkka Seppä

IS

6

Publications

215

Citations

6

H-Index

2016

Active since

Affiliations

Tampere University(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Ilkka Seppä is an author at Tampere University specializing in medicine, vaccinology, and vaccination.

ORCID

Top concepts

Publications per year

2016–2023

6

Publications

6

Effectiveness of the 10-Valent Pneumococcal Nontypeable<i>Haemophilus influenzae</i>Protein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland

Timo Vesikari, Aino Forstén, Ilkka Seppä et al. · Journal of the Pediatric Infectious Diseases Society · 2016 · 81 citations · Full text

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months

Arabella Stuart, Miia Virta, Kristi L. Williams et al. · The Journal of Infectious Diseases · 2022 · 37 citations · Full text

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study

Elmar A. Joura, Àngels Ulied, Corinne Vandermeulen et al. · Vaccine · 2021 · 36 citations

, , +15

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study

Stéphanie Pépin, Henryk Szymański, Ilya Angélica Rochín Kobashi et al. · Human Vaccines & Immunotherapeutics · 2016 · 25 citations · Full text

Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)

Thomas Benfield, Mika Rämet, Piero Valentini et al. · Vaccine · 2023 · 20 citations · Full text

Rows per page

1–5 of 6